SAFE Study - Septal Pacing for Atrial Fibrillation Suppression Evaluation

NCT ID: NCT00419640

Last Updated: 2019-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

385 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, parallel, single-blinded multi-center study. The objective is to compare the long term clinical outcomes among the site of atrial pacing and to compare the long term effect of the atrial fibrillation (AF) Suppression algorithm.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LAS + DAO ON

The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned ON.

Group Type EXPERIMENTAL

Pacemaker implantation with RA lead in LAS position

Intervention Type DEVICE

Pacemaker implantation with RA lead placed in low atrial septal position

LAS + DAO OFF

The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned OFF.

Group Type EXPERIMENTAL

Pacemaker implantation with RA lead in LAS position

Intervention Type DEVICE

Pacemaker implantation with RA lead placed in low atrial septal position

RAA + DAO ON

The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned ON.

Group Type EXPERIMENTAL

Pacemaker implantation with RA lead in RAA position

Intervention Type DEVICE

Pacemaker implantation with RA lead placed in right atrial appendage position

RAA + DAO OFF

The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned OFF.

Group Type ACTIVE_COMPARATOR

Pacemaker implantation with RA lead in RAA position

Intervention Type DEVICE

Pacemaker implantation with RA lead placed in right atrial appendage position

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pacemaker implantation with RA lead in LAS position

Pacemaker implantation with RA lead placed in low atrial septal position

Intervention Type DEVICE

Pacemaker implantation with RA lead in LAS position

Pacemaker implantation with RA lead placed in low atrial septal position

Intervention Type DEVICE

Pacemaker implantation with RA lead in RAA position

Pacemaker implantation with RA lead placed in right atrial appendage position

Intervention Type DEVICE

Pacemaker implantation with RA lead in RAA position

Pacemaker implantation with RA lead placed in right atrial appendage position

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Identity ADx DR device Identity ADx DR pacemaker Identity ADx DR pacemaker Identity ADx DR pacemaker

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have a history of paroxysmal AF with documented AF episode within the last 6 months; documentation of AF is required. It can be documented by one of the following:

* Holter documentation and the strip must be at least 30 seconds; OR
* one page of 12-lead electrocardiogram (ECG); OR
* transtelephonic recording for more than 15 seconds.
2. Have a conventional indication for a pacemaker due to either sinus or atrioventricular (AV) node diseases.
3. Provide written informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluations.
4. Be at least 18 years old.

Exclusion Criteria

1. Already implanted with a pacemaker or implantable cardioverter defibrillator (ICD).
2. Are expected to have heart surgery within the next 6 months.
3. Have angina pectoris, New York Heart Association (NYHA) Class III or Class IV.
4. Are expected not to be able to tolerate high rate pacing.
5. Have less than 12 months' life expectancy.
6. Are on the cardiac transplantation list.
7. Are in chronic AF.
8. Have a reversible aetiology of AF (e.g., hyperthyroidism, acute post-cardiac surgery AF, etc.).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chu-Pak Lau, Prof.

Role: PRINCIPAL_INVESTIGATOR

The University of Hong Kong

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Queen Mary Hospital, The University Hospital of Hong Kong

Hong Kong, , Hong Kong

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

References

Explore related publications, articles, or registry entries linked to this study.

Lau CP, Tachapong N, Wang CC, Wang JF, Abe H, Kong CW, Liew R, Shin DG, Padeletti L, Kim YH, Omar R, Jirarojanakorn K, Kim YN, Chen MC, Sriratanasathavorn C, Munawar M, Kam R, Chen JY, Cho YK, Li YG, Wu SL, Bailleul C, Tse HF; Septal Pacing for Atrial Fibrillation Suppression Evaluation Study Group. Prospective randomized study to assess the efficacy of site and rate of atrial pacing on long-term progression of atrial fibrillation in sick sinus syndrome: Septal Pacing for Atrial Fibrillation Suppression Evaluation (SAFE) Study. Circulation. 2013 Aug 13;128(7):687-93. doi: 10.1161/CIRCULATIONAHA.113.001644. Epub 2013 Jul 18.

Reference Type DERIVED
PMID: 23868858 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR04032AF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.